Literature DB >> 34312182

Preparing for the NASH Epidemic: A Call to Action.

Fasiha Kanwal1, Jay H Shubrook2, Zobair Younossi3, Yamini Natarajan4, Elisabetta Bugianesi5, Mary E Rinella6, Stephen A Harrison7, Christos Mantzoros8, Kim Pfotenhauer9, Samuel Klein10, Robert H Eckel11, Davida Kruger12, Hashem El-Serag4, Kenneth Cusi13.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are common conditions with a rising burden. Yet there are significant management gaps between clinical guidelines and practice in patients with NAFLD and NASH. Further, there is no single global guiding strategy for the management of NAFLD and NASH. The American Gastroenterological Association, in collaboration with 7 professional associations, convened an international conference comprising 32 experts in gastroenterology, hepatology, endocrinology, and primary care providers from the United States, Europe, Asia, and Australia. Conference content was informed by the results of a national NASH Needs Assessment Survey. The participants reviewed and discussed published literature on global burden, screening, risk stratification, diagnosis, and management of individuals with NAFLD, including those with NASH. Participants identified promising approaches for clinical practice and prepared a comprehensive, unified strategy for primary care providers and relevant specialists encompassing the full spectrum of NAFLD/NASH care. They also identified specific high-yield targets for clinical research and called for a unified, international public health response to NAFLD and NASH.
© 2021 by the American Diabetes Association.

Entities:  

Year:  2021        PMID: 34312182     DOI: 10.2337/dci21-0020

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  5 in total

1.  4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes-2022.

Authors:  Boris Draznin; Vanita R Aroda; George Bakris; Gretchen Benson; Florence M Brown; RaShaye Freeman; Jennifer Green; Elbert Huang; Diana Isaacs; Scott Kahan; Jose Leon; Sarah K Lyons; Anne L Peters; Priya Prahalad; Jane E B Reusch; Deborah Young-Hyman
Journal:  Diabetes Care       Date:  2022-01-01       Impact factor: 19.112

Review 2.  The diagnosis and management of nonalcoholic fatty liver disease: A patient-friendly summary of the 2018 AASLD guidelines.

Authors:  Ranjeeta Bahirwani; Connor Griffin
Journal:  Clin Liver Dis (Hoboken)       Date:  2022-07-01

3.  Body composition trajectories from birth to 5 years and hepatic fat in early childhood.

Authors:  Catherine C Cohen; Kylie K Harrall; Stephanie P Gilley; Wei Perng; Katherine A Sauder; Ann Scherzinger; Kartik Shankar; Shikha S Sundaram; Deborah H Glueck; Dana Dabelea
Journal:  Am J Clin Nutr       Date:  2022-10-06       Impact factor: 8.472

Review 4.  Growth Hormone and Insulin-Like Growth Factor 1 Regulation of Nonalcoholic Fatty Liver Disease.

Authors:  Laura E Dichtel; Jose Cordoba-Chacon; Rhonda D Kineman
Journal:  J Clin Endocrinol Metab       Date:  2022-06-16       Impact factor: 6.134

5.  Reply to the Letter to the editor "Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD".

Authors:  Hirokazu Takahashi; Keizo Anzai
Journal:  Hepatol Commun       Date:  2022-05-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.